Trusted by the Top Leaders in Pharmacology
Phenotypic screening uncovers otherwise
unpredicted new uses for a drug
We offer access to dozens of animal models of human disease. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.
In Vivo Pharmacology Platforms
The theraTRACE® and opioidTRACE® platforms are our phenotypic screening tools for drug repositioning, drug repurposing, and indications discovery.
State-of-the-art Preclinical Pharmacology Support
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences
Indiana University, Department of Chemistry
About Melior Discovery
More than just a provider of in vivo pharmacology services, Melior is a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning.
Its proprietary theraTRACE® platform enables rapid and cost-effective identification of new therapeutic potential by systematically screening candidates in a diverse array of validated in vivo disease models.
![](/wp-content/uploads/2021/08/Screen-Shot-2021-03-24-at-6.16.59-PM@2x.png)
Serving our community since 2005
Thousands of completed studies
Hundreds of compounds evaluated
Dozens of animal models of human disease
Recent Featured Publications
Browse our recent peer-reviewed publications from our collaborative discovery projects.
In-Vivo Phenotypic Screening: Clinical Proof of Concept for a Drug Repositioning Approach
Ciallella JR, Reaume, AG
Recent Studies using Phenotypic Screening
Increasingly, phenotypic screening is being recognized as the best strategy to uncover otherwise unpredicted new uses of therapeutics.